Healthabout 24 hours ago· 1 min read
FDA Expands Access to Experimental Pancreatic Cancer Drug Ahead of Approval
The FDA is allowing more patients early access to an experimental pancreatic cancer treatment as it awaits official agency approval. The expanded access designation aims to benefit patients facing this devastating disease.
Breakthrough Access Program
The Food and Drug Administration will allow more patients to have early access to a pancreatic cancer drug as the treatment awaits official approval from the agency.
Pancreatic cancer remains one of the most difficult cancers to treat, with historically poor survival rates. This expanded access program represents a significant step in bringing potentially life-saving treatments to patients faster.